Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Korovit is an oral cardiovascular medication developed and manufactured by Robugen, primarily indicated for the treatment of functional circulatory disorders and hypotension. It is a combination product containing D-camphor and a thick extract of hawthorn berries (Crataegus). Camphor acts as a circulatory stimulant by targeting the vasomotor centers in the central nervous system, leading to increased peripheral vascular tone and blood pressure stabilization. Hawthorn extract provides cardiotonic support, traditionally used to enhance cardiac efficiency and improve blood flow through positive inotropic effects. The drug is approved in Germany as a traditional herbal medicine for supporting cardiovascular function, particularly in cases of orthostatic dysregulation or age-related circulatory instability.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Korovit.